

Pharmacy Formulary Updates for March 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. The changes below are reflected in our online drug list.

The following is a list of drugs that changed formulary status in March 2021:

Drug Name	Tufts Health Plan Commercial Formularies						
	Massachusetts				Rhode Island		
	Large Group 3-Tier Formulary	Large Group 4-Tier Formulary	Small Group/ Individual 3- Tier (Exchange Formularies)	Small Group/ Individual 4-Tier (Exchange Formularies)	Large Group 3-Tier Formulary	Large Group 4-Tier Formulary	Small Group/ Individual 4-Tier (Exchange Formularies)
Lampit	Tier 3						
Ongentys®	Tier 3; PA; QL						
Danylza®	MB						
Oxlumo™	MB; PA						
Nyvepria™	Tier 3 PA, SP, QL	Tier 4 PA, SP, QL	Tier 3 PA, SP, QL	Tier 4 PA, SP, QL	Tier 3 PA, QL	Tier 4 PA, QL	Tier 4 PA, QL
Hemady™	NC, CM						
Alkindi®	NC						
Cystadrops	Tier 2	Tier 4	Tier 2	Tier 4	Tier 2	Tier 4	Tier 4
Eysuvis	NC, QL						
Dificid® suspension	T 3; PA						
Xywav™	Tier 3; QL						
zolmitriptan nasal spray 2.5 and 5 mg/spray unit	Tier 2; STPA - Step 2; QL						
clindamycin phosphate-tretinoin gel 1.2-0.025%	NC						

Key:

MM	Managed Mail – must fill at mail order pharmacy	SP	Specialty Pharmacy
NC	Not covered	ST^{PA}	Step Therapy Prior Authorization
PA	Prior Authorization	MB	Medical Benefit
QL	Quantity Limitation	SI	Specialty Infusion